Hackensack Meridian Health Offers Innovative PSMA PET Imaging Test to Aid in Diagnosis of Prostate Cancer
Newswise — Hackensack, N.J.-- Hackensack Meridian Health announced the availability of PYLARIFY® (piflufolastat F 18) injection, an innovative pros...
Newswise — Hackensack, N.J.-- Hackensack Meridian Health announced the availability of PYLARIFY® (piflufolastat F 18) injection, an innovative prostate cancer imaging test, at four hospitals in the HMH network. Approved in May 2021, the injection is given to a patient through a vein in the arm. That injection binds to prostate cancer cells sending a radio signal which, during a PET scan, shows where the drug is gathering to indicate where the cancer is. A three dimensional picture of the inside of the body, enables doctors to see lymph nodes, bone, and soft tissue metastasis (spread) to determine the presence or absence of recurrent and/or metastatic prostate cancer.